CRISPR in the North American popular press.


Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
10 2019
Historique:
received: 05 12 2018
accepted: 27 02 2019
pubmed: 13 4 2019
medline: 18 3 2020
entrez: 13 4 2019
Statut: ppublish

Résumé

CRISPR is often called one of the century's most important discoveries and is commonly discussed in terms of its momentous potential impacts. This study analyzed how CRISPR is discussed in the North American popular press, including how it is defined, and which benefits and risks/concerns are attributed to the technology. Using the Factiva database, we identified 228 relevant, nonduplicated articles containing either "CRISPR" or "C.R.I.S.P.R.," published in popular US and Canadian news sources between 1 January 2012 and 12 July 2017. Content analysis was performed on the articles. CRISPR is most often discussed in the context of human health (83.8%), compared with animals (26.3%) and plants (20.6%). Nearly all articles (96.1%) presented CRISPR's potential benefits; 61.4% of articles presented CRISPR-related risks/concerns, the vast majority of which focused on the uncertainty surrounding CRISPR, specifically with respect to germline modifications. Overall, the discourse suggests a strong promotion of CRISPR, but an element of caution is also evident. Technical as well as ethical, legal, and social risks/concerns play a prominent role. This media portrayal of CRISPR might help facilitate more sophisticated and balanced policy responses, where the scientific potential of the technology is highlighted alongside broader social considerations.

Identifiants

pubmed: 30976097
doi: 10.1038/s41436-019-0482-5
pii: S1098-3600(21)04486-5
pmc: PMC6774996
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2184-2189

Références

Nat Biotechnol. 2016 Sep 08;34(9):933-941
pubmed: 27606440
Biochem Med (Zagreb). 2012;22(3):276-82
pubmed: 23092060
J Bioeth Inq. 2018 Sep;15(3):327-335
pubmed: 29968018
Science. 2005 Feb 18;307(5712):1028
pubmed: 15718439
EMBO Rep. 2015 Aug;16(8):879-80
pubmed: 26138102
JAMA. 2002 Feb 13;287(6):773
pubmed: 11851549
Sci Transl Med. 2015 Mar 11;7(278):278ps4
pubmed: 25761887
Genet Med. 2018 Sep;20(9):950-956
pubmed: 29300377
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
PLoS One. 2016 Nov 9;11(11):e0166140
pubmed: 27829008
Nat Biotechnol. 2015 May;33(5):478-86
pubmed: 25965754
Genet Med. 2007 Dec;9(12):850-5
pubmed: 18091435

Auteurs

Alessandro Marcon (A)

Health Law Institute, Faculty of Law, University of Alberta, Edmonton, AB, Canada.

Zubin Master (Z)

Biomedical Ethics Research Program and Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, USA.

Vardit Ravitsky (V)

School of Public Health, University of Montreal, Montreal, QC, Canada.

Timothy Caulfield (T)

Faculty of Law and School of Public Health, Health Law Institute, University of Alberta, Edmonton, AB, Canada. caulfield@ualberta.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH